Interaksi Siklosporin dan Repaglinid

Siklosporin dan Repaglinid: kedua label peresepan menguraikan interaksi yang biasanya memerlukan pemantauan, perubahan dosis, atau pemberian jarak antardosis.

Moderat

Biasanya dapat dikelola dengan pemantauan atau perubahan dosis. Beri tahu apoteker Anda bahwa Anda menggunakan keduanya.

Apa kata label FDA

Dari label Siklosporin (Neoral) · berlaku sejak 2026-08-10

Moderat

Cyclosporine may reduce the clearance of digoxin, colchicine, prednisolone, HMG-CoA reductase inhibitors (statins), aliskiren, bosentan, dabigatran, repaglinide, NSAIDs, sirolimus, etoposide, and other drugs.

Interaksi obatmenyebut RepaglinidLihat label di DailyMed
Moderat

Repaglinide Cyclosporine may increase the plasma concentrations of repaglinide and thereby increase the risk of hypoglycemia.

Interaksi obatmenyebut RepaglinidLihat label di DailyMed
Moderat

In 12 healthy male subjects who received two doses of 100 mg cyclosporine capsule orally 12 hours apart with a single dose of 0.25 mg repaglinide tablet (one-half of a 0.5 mg tablet) orally 13 hours after the cyclosporine initial dose, the repaglinide mean C max and AUC were increased 1.8-fold (range, 0.6 to 3.7-fold) and 2.4-fold (range, 1.2 to 5.3-fold), respectively.

Interaksi obatmenyebut RepaglinidLihat label di DailyMed
Moderat

Close monitoring of blood glucose level is advisable for a patient taking cyclosporine and repaglinide concomitantly.

Interaksi obatmenyebut RepaglinidLihat label di DailyMed
Moderat

Caution is also required when cyclosporine is coadministered with potassium sparing drugs (e.g., angiotensin converting enzyme inhibitors, angiotensin II receptor antagonists), potassium-containing drugs as well as in patients on a potassium rich diet.

Interaksi obatberdasarkan golongan obatLihat label di DailyMed

Dari label Repaglinid (Repaglinide) · berlaku sejak 2025-05-02

Moderat

Cyclosporine Clinical Impact: Cyclosporine increased low dose repaglinide exposures by 2.5 fold [see Clinical Pharmacology (12.3) ] Intervention: Daily maximum repaglinide tablets dose should be limited to 6 mg, and increased frequency of glucose monitoring may be required when repaglinide tablets are co-administered with cyclosporine.

Interaksi obatmenyebut SiklosporinLihat label di DailyMed
Moderat

Cyclosporine : Limit daily dose of repaglinide to 6 mg and increase frequency of glucose monitoring when co-administered ( 7 )

Interaksi obatmenyebut SiklosporinLihat label di DailyMed
Moderat

CYP2C8 and CYP3A4 Inhibitors Intervention: Repaglinide tablets dose reductions and increased frequency of glucose monitoring may be required when co‑administered.

Interaksi obatberdasarkan golongan obatLihat label di DailyMed
Moderat

CYP2C8 and CYP3A4 Inhibitors and Drugs That May Increase the Risk of Hypoglycemia : Co-administration may require repaglinide tablets dose reductions and increased frequency of glucose monitoring ( 7 )

Interaksi obatberdasarkan golongan obatLihat label di DailyMed
Minor

Examples: Drugs that are known to inhibit CYP3A4 include antifungal agents (ketoconazole, itraconazole) and antibacterial agents (clarithromycin, erythromycin).

Interaksi obatberdasarkan golongan obatLihat label di DailyMed

Menggunakan lebih dari dua obat ini? Interaksi saling bertumpuk. Periksa seluruh daftar Anda sekaligus; daftar itu tetap berada di peramban Anda.

Buka di pemeriksa

Bukan nasihat medis. Interaction Checker mengutip teks label FDA dan lembar fakta NIH. Penting atau tidaknya suatu interaksi bagi Anda bergantung pada dosis, waktu penggunaan, fungsi ginjal dan hati, serta kondisi lain. Pastikan dengan apoteker atau dokter yang meresepkan.